21-Aug-2026 15:36:28

AUROBINDO PHARMA : US FDA INSPECTION CONCLUDES AT SUBSIDIARY

• AuroPeptides Ltd, a subsidiary, was inspected by the US FDA from August 17-21, 2026. • The inspection was routine and covered facility and equipment maintenance. • Only one observation was noted, not related to data integrity or GMP compliance. • Corrective action has been initiated and a formal response will be submitted.

Aurobindo Pharma Limited

← Back to feed